Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman
31 Ottobre 2018 - 10:00PM
Business Wire
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical
company focused on the development and commercialization of novel
gastrointestinal (GI) therapies, today announced that Melvin K.
Spigelman, M.D., who has served as an Independent Director of
Synergy since August 2008, will now assume the role of Chairman of
the Board, effective immediately. Synergy’s outgoing Executive
Chairman, Gary S. Jacob, Ph.D., will leave the Company to pursue
other opportunities.
“As a co-inventor of plecanatide, Gary played a critical role in
the discovery, development and FDA approval of Synergy’s first
product, TRULANCE®, which is now available to help benefit patients
suffering from chronic GI conditions,” said Troy Hamilton, Chief
Executive Officer of Synergy Pharmaceuticals Inc. “We thank Gary
for more than a decade of service to Synergy and wish him well in
his future endeavors.”
About Synergy Pharmaceuticals
Synergy is a biopharmaceutical company focused on the
development and commercialization of novel gastrointestinal (GI)
therapies. The company has pioneered discovery, research and
development efforts around analogs of uroguanylin, a naturally
occurring human GI peptide, for the treatment of GI diseases and
disorders. Synergy’s proprietary GI platform includes one
commercial product TRULANCE® (plecanatide) and a second product
candidate – dolcanatide. For more information, please
visit www.synergypharma.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of forward-
looking words such as "anticipate," "planned," "believe,"
"forecast," "estimated," "expected," and "intend," among others.
These forward-looking statements are based on Synergy's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our ability to continue as a going concern; our need
for additional financing; whether we can obtain financing on
commercially reasonable terms; our ability to meet our obligations
under the term loan agreement; uncertainties of patent protection
and litigation; uncertainties of government or third party payer
reimbursement; limited sales and marketing efforts and dependence
upon third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As
with any pharmaceutical under development, there are significant
risks in the development, regulatory approval and commercialization
of new products. There are no guarantees that future clinical
trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for
any indication or prove to be commercially successful. Investors
should read the risk factors set forth in Synergy's Annual Report
on Form 10-K for the year ended December 31, 2017 and other
periodic reports filed with the Securities and Exchange Commission.
While the list of factors presented here is considered
representative, no such list should be considered to be a complete
statement of all potential risks and uncertainties. Unlisted
factors may present significant additional obstacles to the
realization of forward-looking statements. Forward-looking
statements included herein are made as of the date hereof, and
Synergy does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181031005846/en/
For Synergy PharmaceuticalsTed McHugh and Nicole
Briguet212-584-7610SynergyIR@edelman.com
Grafico Azioni Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Storico
Da Giu 2023 a Giu 2024